RevvityRVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $1.16M
18% more repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 168
14% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 50
2.42% more ownership
Funds ownership: 91.52% [Q4 2024] → 93.94% (+2.42%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0% less funds holding
Funds holding: 519 [Q4 2024] → 518 (-1) [Q1 2025]
10% less capital invested
Capital invested by funds: $13.2B [Q4 2024] → $11.9B (-$1.28B) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Raymond James Andrew Cooper | 22%upside $115 | Outperform Reiterated | 29 Jul 2025 |
Stifel Daniel Arias | 16%upside $110 | Hold Maintained | 29 Jul 2025 |
Evercore ISI Group Vijay Kumar | 22%upside $115 | Outperform Maintained | 8 Jul 2025 |
B of A Securities Derik De Bruin | 16%upside $110 | Buy Maintained | 26 Jun 2025 |
UBS Dan Leonard | 22%upside $115 | Buy Upgraded | 1 May 2025 |
Financial journalist opinion
Based on 18 articles about RVTY published over the past 30 days
